中国科学院上海有机化学研究所生物与化学交叉研究中心主任。2000年至2020年曾任美国哈佛大学医学院细胞生物学系终身教授，2014年至2020年任哈佛大学医学院Elizabeth. D. Hay教授。已故的Elizabeth. D. Hay教授是哈佛医学院历史上第一位女性正教授。2020年袁钧瑛全职回国工作。袁钧瑛教授是美国科学学院院士，美国艺术和科学院院士，美国科学促进会会士。袁钧瑛教授在细胞死亡领域作出了多个重要开创性贡献，是国际学术界公认的细胞死亡研究领域里的权威, 曾获得各种国际奖项和荣誉11项。袁钧瑛教授是世界上第一个细胞凋亡基因的发现者。并首先发现了细胞坏死的可调控性和世界上第一个细胞坏死的小分子抑制剂，为世界细胞凋亡和坏死领域奠定了研究基础。
YUAN Junying received her undergraduate degree from Fudan University, Shanghai, China, in 1982 and her Ph.D. in Neuroscience from Harvard University in 1989. Dr. Yuan carried out her Ph.D. thesis work at the Massachusetts Institute of Technology in the laboratory of H. R. Horvitz. She was first appointed as Assistant Professor at Harvard Medical School in 1992, when she became a Principal Investigator of the Cardiovascular Research Center at Massachusetts General Hospital. She joined the Department of Cell Biology in 1996 and was appointed a Professor of Cell Biology at Harvard Medical School in 2000. In 2014, Dr. Yuan was appointed as Elizabeth D. Hay Professor of Cell Biology, a Professorship honors the late Professor Elizabeth D. Hay, the first female full professor in the history of Harvard Medical School. Dr. Yuan returned to China in 2020 and joined Shanghai Institute of Organic Chemistry as the Founding Director of Interdisciplinary Research Center on Biology and Chemistry.
Dr. Yuan is a pioneer and an influential leader in the cell death field. Her 230 published papers have been highly cited with collective citations of more than 100,000 times (H index 126). Dr. Yuan made transformative discoveries on two distinct forms of cell death, apoptosis and necroptosis in mammalian cells. Her discovery of mammalian caspases led to a molecular era in apoptosis research. Her development of necrostatins demonstrated the existence and significance of a regulated necrosis mechanism, termed necroptosis, in human inflammatory and neurodegenerative diseases and the role of RIPK1 as a key mediator of necroptosis. RIPK1 inhibitors, first discovered and described by Dr. Yuan, have been advanced into human clinical trials as new drugs for the treatment of amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD) as well as inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis, psoriasis and COVID-19 around the world. Dr. Yuan’s accomplishments have been honored by many awards including the Innovator Award for Breast Cancer Research, NIH Director’s Pioneer award and Agilent Technologies Thought Leader Award. She is a member of the National Academy of Sciences (US), a fellow of the American Academy of Arts and Sciences and a fellow of the American Association for the Advancement of Sciences.
© Copyright 2020-2022 中国细胞生物学学会 版权所有